Background: Nowadays, with the emergence of vancomycin-resistant strains, the clinical use of vancomycin has been followed closely by applying the antimicrobial stewardship program (ASP) to enhance effectiveness in treatment and reduce cost burden for patients.
Methods: A descriptive cross-sectional study at the Hospital for Tropical Diseases was conducted to assess the inpatient status assigned to intravenous vancomycin and factors associated with the cost of treatment during two periods of implementing ASP, which were i) from April 1, 2016 to March 31, 2018 (previous ASP-pASP) and ii) from June 1, 2018 to March 31, 2020 (new ASP-nASP).
Results: Among 1375 patients who met the sampling criteria, there were 601 and 774 patients in pASP and nASP, respectively. The rate of no improvement/mortality in the pASP was higher than that in nASP (37.10% vs 25.98%, p <0.05). The proportion of patients with two or more infection episodes in nASP is lower than that in pASP (9.83% vs 18.64%, p<0.05). Besides, nASP has higher length of therapy (LOT) and higher day of therapy (DOT). The average treatment cost in the pASP is higher than that in the nASP, 1891.22 (95% CI, 1713.46-2068.98) USD vs 1775.55 (95% CI, 1576.22-1974.88) USD. There are seven factors (p<0.05) that associate with the total cost of treatment (age, number of infection episodes, length of stay, discharge status, clinical department, LOT, DOT) in pASP. On the other hand, the nASP has five factors (p<0.001), in which the log(LOT) and age are not as statistically significant (p=0.5127 and 0.3852, respectively) as in the pASP model.
Conclusion: The implementation and improvement of the ASP at the Hospital for Tropical Diseases have initially shown benefits for patients using intravenous vancomycin. Specifically, the ASP helps to reduce treatment costs, improve patient outcomes, reduce length of stay and decrease the average daily dose of vancomycin.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235933 | PMC |
http://dx.doi.org/10.2147/RMHP.S307744 | DOI Listing |
Cureus
December 2024
Biomedical Sciences, Georgian American University (GAU), Tbilisi, GEO.
Background: Nosocomial pneumonia is a significant healthcare challenge, particularly in the face of rising antimicrobial resistance among Gram-negative bacteria. The production of extended spectrum beta-lactamase (ESBL) exacerbates treatment complexities.
Aim: This study investigates the prevalence and resistance patterns of ESBL-producing and non-ESBL Gram-negative bacteria in nosocomial pneumonia cases in Georgian hospitals to inform antibiotic stewardship and treatment strategies.
J Family Med Prim Care
December 2024
Department of Pharmacology, All India Institute of Medical Sciences (AIIMS) Kalyani, Kalyani, West Bengal, India.
The novel approach of "Community Pharmacology" integrates pharmacological principles with community health to achieve the "Health for all" goal through safe and efficient health care. Pharmacovigilance, medication errors (ME), irrational prescriptions, and antimicrobial resistance in the community could be the key areas. Though life expectancy and other health indicators have improved in India, the disparity between rural and urban quality healthcare access should be addressed.
View Article and Find Full Text PDFJ Hosp Infect
January 2025
Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Infectious Diseases, Dept of Diagnostic and Public Health, University Hospital Verona, Verona, Italy; DZIF-Clinical Research Unit, Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.
Background: ESBL-producing Enterobacterales (ESBL-PE) are highly prevalent in long-term healthcare (LTCF) settings. In order to estimate the acquisition rate of ESBL-producing Escherichia coli and Klebsiella pneumoniae in LTCF settings and identify clinical and environmental risk factors, a multicentric, prospective cohort study was conducted in six LTCFs in Germany, France, Spain and the Netherlands.
Methods: Longitudinal screening of residents was performed over 32 weeks, collecting epidemiological and clinical data and environmental samples.
Can Commun Dis Rep
January 2025
Data, Surveillance and Foresight Branch, Public Health Agency of Canada, Ottawa, ON.
Background: Antimicrobial resistance (AMR) is associated with significant human and financial costs, particularly among vulnerable populations like older adults living in long-term care homes (LTCHs). Urinary tract infection (UTI) is the leading indication for antibiotic use in this population, with some estimates suggesting that up to 70% of these prescriptions may be avoidable.
Objective: The purpose of this study is to develop and test novel behavioural science-informed antimicrobial stewardship (AMS) quality improvement strategies in Canadian LTCHs, which aim to decrease unnecessary testing and treatment for residents who lack the minimum clinical signs and symptoms of UTI.
Age Ageing
January 2025
School of Medicine, University of Dundee, Dundee, UK.
Background: There is wide variation in antibiotic prescribing across care-homes for older people, with implications for resident outcomes and antimicrobial resistance.
Objective: To quantify variation in antibiotic prescribing and associations with resident, care-home and general practice characteristics.
Design: Population-based analyses using administrative data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!